May 2004
Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          
Apr   Jun


For more search options, please see the Advanced search form and the section of the User's Guide, Tips for Searching PULSE.


C H A N N E L S
PULSE Home Page
EXECUTIVE EDITION

US News
Canada News
UK News
New Zealand News

Consumer Advocacy
Health Care Systems
Managed Care/Medicaid
Co-occurring Disorders
Clinical studies
Pharmaceutical News
Criminal Justice Systems
Legislative News


U S E R ' S   G U I D E
About PULSE
PULSE Channels

Archives

Adding comments

Using the # link

Items that require registration

PULSE syndication

Tips for Searching PULSE


E M A I L   S U B S C R I P T I O N S

For WEEKLY summaries of PULSE postings, see the weekly email subscription form.

For DAILY mailings (powered by Bloglet), please enter your e-mail address below:


P U B L I C A T I O N S

PULSE ANNUAL No. 2
January 2003

Recent Trends, Challenges and Issues in Funding Public Mental Health Services in the US
March 2002

PULSE ANNUAL No. 1
October 2001

 

PULSE is powered by
Radio Userland
.

Listed on BlogShares

© Bill Davis, 2000-2003.

About PULSE | Channels | User's Guide | Email subscriptions | Publications




PULSE is a free service of the Centre for Community Change International, gathering new and noteworthy Internet resources for mental health providers, family members of individuals with mental illness, consumers of mental health services and consumer advocates. PULSE is researched, edited and designed by Bill Davis.



daily link  Monday, May 10, 2004


The Use of Dual-Action Antidepressants in the Treatment of Depression
Article at Medscape Psychiatry & Mental Health - " Since the late 1980s, with the introduction of fluoxetine, the first selective serotonin reuptake inhibitor (SSRI) antidepressant, the treatment of depression has become much more of a commonplace phenomenon. The SSRIs' efficacy, side-effect profile, and safety allowed the pharmacologic treatment of depression to take a huge leap. Because of the ease of prescribing these agents and their wide therapeutic index, nonpsychiatric practitioners increasingly began to utilize them in the treatment of depression in primary care settings. However, it quickly became apparent that the SSRIs were not a panacea for the treatment of depression. As much as 30% to 40% of patients did not respond to these agents, and many responders never did achieve full remission of their depressive symptoms. Onset of action continued to be slow, with at least 3-4 weeks needed to assess if the medication would be effective. SSRIs were not free of side effects, with sexual dysfunction, gastrointestinal effects, and increased anxiety commonplace complaints from patients..." [Viewing Medscape resources requires registration, which is free].  
permalink  


One Drug Treats Both Sides of Bipolar Disorder
Health Day News story at Yahoo - "For the first time, doctors have found a single drug that can treat both the manic and depressive phases of bipolar disorder. The antipsychotic medication Seroquel currently is approved for short-term treatment of acute manic episodes. But findings presented May 5 at the annual meeting of the American Psychiatric Association in New York City show it also is effective in treating depressive episodes. The study involved a randomized trial of 542 patients with bipolar depression at 39 sites in the United States..."  
permalink